<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275351</url>
  </required_header>
  <id_info>
    <org_study_id>SM04554-AGA-02</org_study_id>
    <nct_id>NCT02275351</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosplice Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosplice Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, and efficacy of&#xD;
      topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with&#xD;
      Androgenetic Alopecia (AGA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in non-vellus hair count</measure>
    <time_frame>Baseline, Day 45, Day 90</time_frame>
    <description>Change in non-vellus hair count over time as compared to Baseline. Non-vellus hair count will be determined by macrophotography.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in subject assessment of hair growth and quality</measure>
    <time_frame>Day 45, Day 90</time_frame>
    <description>Change in Men's Hair Growth Questionnaire (MHGQ) over time as compared to Baseline. The MHGQ is a subject-completed assessment that asks the subject to evaluate his hair growth and quality since the start of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hair growth as assessed by the investigator</measure>
    <time_frame>Day 45, Day 90</time_frame>
    <description>Change in hair growth over time as compared to Baseline, as assessed by the investigator, using a 7-point scale from -3 (greatly decreased) to +3 (greatly increased).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of AGA on quality of life</measure>
    <time_frame>Baseline, Day 45, Day 90</time_frame>
    <description>Change in subject responses to the Kingsley Alopecia Profile (KAP) questionnaire over time as compared to Baseline. The KAP is a 38-question survey completed by each subject that assesses his quality of life in relation to AGA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hair density</measure>
    <time_frame>Baseline, Day 45, Day 90</time_frame>
    <description>Change in hair density over time as compared to Baseline. Hair density will be measured using macrophotography.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Active Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04554 0.15% solution, applied once a day for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical SM04554 0.25% solution, applied once a day for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical vehicle solution, applied once a day for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM04554</intervention_name>
    <description>Topical solution, applied once a day</description>
    <arm_group_label>Active Arm 1</arm_group_label>
    <arm_group_label>Active Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Topical solution, applied once a day</description>
    <arm_group_label>Vehicle Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of AGA&#xD;
&#xD;
          -  Willing to inform females, with whom they may interact, that they are using a topical&#xD;
             investigational product and direct contact should be avoided as potential harm to a&#xD;
             fetus is unknown&#xD;
&#xD;
          -  Willing to maintain the same hair style as at study start for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Willing to not use semi-permanent hair products (e.g., color, texturizers, relaxers)&#xD;
             for the duration of the study. Daily styling products will be allowed (e.g., hair gel,&#xD;
             mousse, styling spray).&#xD;
&#xD;
          -  Willing to use a mild non-medicated shampoo and conditioner for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Willing to receive a small scalp tattoo&#xD;
&#xD;
          -  Able to read and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia&#xD;
&#xD;
          -  Scalp hair loss on the treatment area, due to disease, injury, or medical therapy&#xD;
&#xD;
          -  Males who are sexually active and have a partner who is capable of becoming pregnant,&#xD;
             neither of whom have had surgery to become sterilized, that are not using an effective&#xD;
             method of birth control and are not willing to use an effective method of birth&#xD;
             control during the study treatment period until 90 days post last dose of study&#xD;
             medication&#xD;
&#xD;
          -  Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun&#xD;
             damage, seborrheic dermatitis), cuts and/or abrasions on the scalp or condition (e.g.,&#xD;
             sunburn, tattoos) on the treatment area that, in the opinion of the Investigator,&#xD;
             might put the subject at risk or interfere with the study conduct or evaluations&#xD;
&#xD;
          -  History of surgical correction of hair loss on the scalp&#xD;
&#xD;
          -  Previous exposure to SM04554&#xD;
&#xD;
          -  Use of any products or devices purported to promote scalp hair growth (e.g.,&#xD;
             finasteride or minoxidil) within the 24 weeks prior to study start&#xD;
&#xD;
          -  Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone&#xD;
             acetate, cimetidine) within 12 weeks prior to study start&#xD;
&#xD;
          -  History of hair transplants&#xD;
&#xD;
          -  Current use of an occlusive wig, hair extensions, or hair weaves&#xD;
&#xD;
          -  Participation in any other investigational drug or medical device trial, which&#xD;
             included administration of an investigational study medication or medical device,&#xD;
             within 30 days or 5 half-lives of the investigational agent, whichever is longer,&#xD;
             prior to study start&#xD;
&#xD;
          -  Subjects with a history of clinically significant cardiac arrhythmia as determined by&#xD;
             the Investigator&#xD;
&#xD;
          -  Subjects with clinically significant findings from medical history, clinical&#xD;
             laboratory tests, electrocardiogram (ECG), or vital signs that, in the opinion of the&#xD;
             Investigator, could interfere with the objectives of the study or put the subject at&#xD;
             risk&#xD;
&#xD;
          -  Subjects unwilling to refrain from sperm donation during the study treatment period&#xD;
             until 90 days post last dose of study medication&#xD;
&#xD;
          -  Subjects with pregnant partners at study start&#xD;
&#xD;
          -  Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30&#xD;
             days prior to study start&#xD;
&#xD;
          -  Use of medicated shampoo or conditioner within 30 days prior to study start&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Yazici, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Biosplice Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <disposition_first_submitted>July 24, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 24, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 26, 2018</disposition_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alopecia</keyword>
  <keyword>topical</keyword>
  <keyword>Samumed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

